Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Dimitra, Vyrla"'
Autor:
Maria G. Daskalaki, Dimitra Vyrla, Maria Harizani, Christina Doxaki, Aristides G. Eliopoulos, Vassilios Roussis, Efstathia Ioannou, Christos Tsatsanis, Sotirios C. Kampranis
Publikováno v:
Marine Drugs, Vol 17, Iss 2, p 97 (2019)
Macrophages are central mediators of inflammation, orchestrating the inflammatory response through the production of cytokines and nitric oxide. Macrophages obtain pro-inflammatory (M1) and anti-inflammatory (M2) phenotypes, which can be modulated by
Externí odkaz:
https://doaj.org/article/0234fb9a86d34c40804438f81dafd3b5
Autor:
Konstantina Stathopoulou, Dimitra Vyrla, L. Jeffrey Medeiros, Elias Drakos, George Z. Rassidakis, Vaios Sinatkas, Vasilios Atsaves, Ioanna Xagoraris, Jingjing Ye, Vasiliki Leventaki
Publikováno v:
Leukemia & Lymphoma. 62:1563-1573
We hypothesized that murine double minute X (MDMX), a negative p53-regulator, may be involved in dysfunctional p53-signaling in anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK)-positive and ALK-negative, characterized frequentl
Autor:
Dimitra Vyrla
Kλινικές και επιδημιολογικές μελέτες παρέχουν στοιχεία που υποστηρίζουν ότι η φλεγμονή και η επαγόμενη βλάβη του ήπατος αποτελούν την κ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3c15884c6bf0885e1046de76be8991f
https://doi.org/10.12681/eadd/37837
https://doi.org/10.12681/eadd/37837
Autor:
Maria G, Daskalaki, Dimitra, Vyrla, Maria, Harizani, Christina, Doxaki, Aristides G, Eliopoulos, Vassilios, Roussis, Efstathia, Ioannou, Christos, Tsatsanis, Sotirios C, Kampranis
Publikováno v:
Marine Drugs
Macrophages are central mediators of inflammation, orchestrating the inflammatory response through the production of cytokines and nitric oxide. Macrophages obtain pro-inflammatory (M1) and anti-inflammatory (M2) phenotypes, which can be modulated by
Publikováno v:
Cancers
Cancers, Vol 11, Iss 8, p 1097 (2019)
Cancers, Vol 11, Iss 8, p 1097 (2019)
Apolipoprotein A-I (ApoA-I), the major protein component of high-density lipoproteins (HDL) is a multifunctional protein, involved in cholesterol traffic and inflammatory and immune response regulation. Many studies revealing alterations of ApoA-I du
Autor:
Maria J. Perugorria, Jelena Mann, Fiona Oakley, Jayashree Bagchi Chakraborty, Dimitra Vyrla, Lindsay B. Murphy, Nicola Fullard, Caroline L. Wilson, Derek A. Mann
Publikováno v:
Hepatology. 57:1238-1249
Toll-like receptors (TLRs) function as key regulators of liver fibrosis and are able to modulate the fibrogenic actions of nonparenchymal liver cells. The fibrogenic signaling events downstream of TLRs on Kupffer cells (KCs) and hepatic stellate cell
Autor:
Derek A. Mann, Dimitra Vyrla, Georgios Nikolaidis, Fiona Oakley, Philip N. Tsichlis, Maria J. Perugorria, Aristides G. Eliopoulos
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 196(10)
Invariant NKT (iNKT) cells represent a subset of innate-like T lymphocytes that function as orchestrators of hepatic inflammation underpinning liver damage. In this study, we demonstrate that TPL2, an MAP3 kinase that has mostly been appreciated for
Autor:
Philip N. Tsichlis, Kalliopi Gkouskou, Aristides G. Eliopoulos, Kostantinos Evangelou, Dimitra Vyrla, John K. Field, Triantafillos Liloglou, Vasiliki Pelekanou, Dimitris C. Kanellis, Georgios Nikolaidis, Urszula Oleksiewicz, Efstathios N. Stathopoulos, Michalis Liontos, Vassilis G. Gorgoulis, Katerina Gkirtzimanaki
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 110(16)
Lung cancer is a heterogeneous disease at both clinical and molecular levels, posing conceptual and practical bottlenecks in defining key pathways affecting its initiation and progression. Molecules with a central role in lung carcinogenesis are like
Autor:
Dimitra Vyrla, Katerina Gkirtzimanaki, Angelica Loskog, Lina Liljenfeldt, Emma Svensson, Aristides G. Eliopoulos
Publikováno v:
Cancer Immunology, Immunotherapy; Vol 63
Bystander immune activation by chemotherapy has recently gained extensive interest and provided support for the clinical use of chemotherapeutic agents in combination with immune enhancers. The CD40 ligand (CD40L; CD154) is a potent regulator of the